U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07252661) titled 'Study of ACC-1898 in Adult Participants With Advanced Solid Tumors' on Nov. 18.
Brief Summary: This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
The purpose of this Phase 1 clinical trial is to find a safe dose of ACC-1898 and to understand how the body absorbs, distributes, and eliminates the drug (pharmacokinetics / PK). The study will also look for early signs that ACC-1898 may slow or shrink tumors and explore possible biological markers related to drug activity.
Adults with adva...